Updated: 22 hours ago
Medically reviewed by Dr Eric Wang- ChinaCureLink Team
An international patient with uterine cancer may need a surgeon who can stage an early tumor, or a team that can explain what the tumor’s genetic test means after treatment has stopped working. Those are different referrals, even when the hospital names on the shortlist are the same.
For endometrial cancer, compare the gynecologic oncology teams at the Cancer Hospital, Chinese Academy of Medical Sciences in Beijing, Sun Yat-sen University Cancer Center in Guangzhou, and Fudan University Shanghai Cancer Center. The best fit depends on the pathology, stage, and next treatment decision. A diagnosis of uterine sarcoma calls for a sarcoma specialist’s review.
Key Takeaways |
• For endometrial cancer, compare teams by surgical staging and molecular testing. • Uterine sarcoma calls for a separate specialist review. • China has conditionally approved two combinations for defined groups after prior treatment. • Confirm eligibility, costs, and follow-up before travel. |
Table of Contents
What to Look For in a Uterine Cancer Hospital in China
Endometrial carcinoma starts in the lining of the uterus. Uterine sarcomas, including leiomyosarcoma and endometrial stromal sarcoma, arise from different tissues and follow separate treatment pathways. Cervical cancer begins in the cervix. When comparing a uterine cancer hospital in China, it is important to understand that the exact diagnosis on the pathology report determines which specialist should review the case and recommend an appropriate treatment approach.
For many patients with apparently early endometrial cancer, treatment starts with a hysterectomy and removal of the fallopian tubes and ovaries. The team may use sentinel lymph node mapping to check the first nodes likely to receive cancer cells. The need for radiation or chemotherapy afterward depends on stage, tumor features, and molecular classification. For more on arranging cancer treatment in China, see the general patient guide.
Ask whether the report includes MMR, p53, and POLE results where appropriate. Mismatch repair testing, often labeled MMR or MSI, can help guide immunotherapy decisions and identify patients who may need a Lynch syndrome assessment. Someone with a suspected sarcoma should seek specialist pathology review and an operation plan tailored to that subtype.
Two China-Approved Options After Prior Treatment
China conditionally approved fruquintinib plus sintilimab for previously treated advanced endometrial cancer with proficient mismatch repair (pMMR) when surgery or radiation aimed at cure is unsuitable. In the Chinese phase 1b/2 FRUSICA-1 study, 32 of 98 patients (32.7%) had a confirmed response. Median time before progression or death was 8.6 months. Grade 3 or higher treatment-related side effects occurred in 60.2%, including high blood pressure and hand-foot reactions.
China also conditionally approved benmelstobart plus anlotinib for an indication covering eligible previously treated recurrent or metastatic endometrial cancer with non-MSI-high or non-dMMR tumors, when curative surgery or radiation is unsuitable. In the 85-patient expansion of China’s phase 2 ETER200 study, 29 patients (34.1%) responded. Median time before progression or death was 8.8 months. Grade 3 or higher treatment-related side effects occurred in 60 of 85 patients (70.6%). Both Chinese studies lacked a comparison arm. When exploring targeted therapy in China, ask about the exact indication, prior immunotherapy, and the monitoring plan.
Three Public Gynecologic Oncology Centers
The shortlist follows a national gynecologic oncology specialty list informed in part by Fudan University’s Hospital Rankings. The positions shown reflect that specialty list. The right team for a patient depends on disease-specific experience and the plan it proposes. Families comparing Beijing hospitals for international patients can check international intake before sending records.
Cancer Hospital, Chinese Academy of Medical Sciences — Beijing
The hospital’s gynecologic oncology department combines surgery, radiotherapy, and chemotherapy. It is a center to consider when a family needs a coordinated review of surgery and treatment afterward.
Sun Yat-sen University Cancer Center — Guangzhou
The gynecologic oncology team treats endometrial cancer and has published institutional information about its research in advanced pMMR disease. Confirm the current status of any study and the campus that will handle the consultation.
Fudan University Shanghai Cancer Center — Shanghai
The center combines gynecologic surgery, radiation, and drug treatment. Its specialists also assess endometrial tumor molecular results, a useful capability when reviewing a treatment plan after surgery or recurrence. The city guide covers practical access to Shanghai hospitals for international patients.
Private Cancer Hospitals in Guangzhou
Fuda lists local procedures such as cryoablation, while Modern Cancer Hospital Guangzhou lists image-guided interventions. Guangzhou Concord Cancer Center lists medical oncology and radiotherapy, and RoyalLee Cancer Hospital describes its radiotherapy program. A private center may be worth comparing when a gynecologic oncology team has identified a role for a specific service. For initial staging surgery or suspected sarcoma, prioritize a team that can review the pathology and explain its experience with the exact diagnosis. Comparable uterine cancer outcome data were unavailable for this public/private comparison.
Costs, Eligibility, and Care After Travel
Compare the plan with options close to home. The US FDA approved pembrolizumab plus carboplatin and paclitaxel for primary advanced or recurrent endometrial carcinoma. The randomized study enrolled 810 patients in the FDA analysis. In pMMR disease, median time before progression or death was 11.1 months with the combination versus 8.5 months with chemotherapy alone. European guidance also uses stage, molecular subtype, and prior treatment to guide therapy.
After prior platinum treatment, pembrolizumab plus lenvatinib is an established option for eligible patients in the US and other markets. At five years, the randomized KEYNOTE-775 trial reported median overall survival of 18.0 versus 12.2 months in its pMMR population, compared with chemotherapy. That trial and the Chinese single-arm studies answer different questions. Their results cannot rank the combinations against each other or settle what to use after prior checkpoint immunotherapy.
For an overseas review, send translated pathology, scan files, biomarker results and a timeline of drug treatment. For cancer clinical trials in China, confirm that the specific site is enrolling and can screen overseas patients. Approval for a defined indication and enrollment in a trial are separate access pathways.
When comparing cancer treatment costs in China, ask for a written estimate that includes pathology review, surgery or drug cycles, inpatient care, and any planned radiation. Confirm exclusions, the expected stay, how toxicities will be managed, and whether monitoring and refills can continue at home.
What to Expect When Booking Directly
A family can approach a hospital’s international patient office with a specific question and request a written opinion, a proposed schedule, and an itemized quote. Check the campus, interpreter arrangements, and whether the named specialist can review the case before travel.
Independent Guidance Before Travel
ChinaCureLink, a Medebound HEALTH company, represents patients and can identify up to three suitable hospitals or specialists. Hospital and specialist matching is free. Video second opinions are paid consultations, with fees confirmed before booking. The initial advisory call is free. See how hospital matching works.
A Published Immunotherapy Case From China
In a Chinese case series published in 2026, a woman with recurrent dMMR endometrioid carcinoma had a pelvic mass measuring 5.6 cm on MRI. After two cycles of off-label sintilimab before surgery, it measured 3.1 cm. The removed tissue showed no viable tumor. The report described continued complete remission at 36 months and grade 2 immune-related thyroid overactivity during treatment.
This was one patient who also underwent surgery. Individual results vary. Seek a second opinion before traveling for a treatment sequence that differs from the standard plan. The original report includes before-and-after MRI images.
What Patients Say About ChinaCureLink & Medebound HEALTH
The following feedback describes experiences with the coordination service.
Practical Next Steps
Confirm the pathology and molecular results. Decide whether the priority is surgery, a treatment after recurrence, or a sarcoma review. Compare qualified teams, get a specialist opinion, and check costs, risks, alternatives, and follow-up before making plans to travel to China for medical treatment.
Frequently Asked Questions
Which Hospital Should an International Patient Contact First?
For endometrial cancer, start with a gynecologic oncologist who can review the original pathology and scans. If the report says leiomyosarcoma or endometrial stromal sarcoma, ask for a sarcoma team with gynecologic surgical expertise.
Can an International Patient Get One of China’s Approved Combinations?
Potentially, if the biomarker, prior treatment, and other clinical details meet the indication and the hospital can prescribe and supply it. Confirm blood pressure monitoring, blood tests, and a plan for care after returning home.
Can Treatment Preserve Fertility?
Selected patients with grade 1 endometrioid cancer confined to the lining of the uterus may be considered for hormone-based treatment with close follow-up. A gynecologic oncologist and fertility team should review eligibility before a patient changes or delays the planned treatment.
How Much Does Uterine Cancer Treatment in China Cost?
Costs depend on the treatment plan. Ask for an itemized quote for pathology, surgery, inpatient days, drug cycles, or radiation, and ask how the hospital bills for complications and extra days.
Bottom Line
A strong uterine cancer hospital can explain why the proposed plan fits the tumor subtype, stage, and prior treatment. A video second opinion can help families compare that plan with care at home before they travel.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
References
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
You may also like:
Learn how to book an oncology appointment in China before traveling.
See how to join a cancer clinical trial in China for the screening process.
